663 related articles for article (PubMed ID: 25234206)
1. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
Zoungas S; Chalmers J; Neal B; Billot L; Li Q; Hirakawa Y; Arima H; Monaghan H; Joshi R; Colagiuri S; Cooper ME; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Lisheng L; Mancia G; Marre M; Matthews DR; Mogensen CE; Perkovic V; Poulter N; Rodgers A; Williams B; MacMahon S; Patel A; Woodward M;
N Engl J Med; 2014 Oct; 371(15):1392-406. PubMed ID: 25234206
[TBL] [Abstract][Full Text] [Related]
2. New insights from ADVANCE.
Chalmers J; Kengne AP; Joshi R; Perkovic V; Patel A
J Hypertens Suppl; 2007 Jun; 25(1):S23-30. PubMed ID: 17579315
[TBL] [Abstract][Full Text] [Related]
3. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON.
Wong MG; Perkovic V; Chalmers J; Woodward M; Li Q; Cooper ME; Hamet P; Harrap S; Heller S; MacMahon S; Mancia G; Marre M; Matthews D; Neal B; Poulter N; Rodgers A; Williams B; Zoungas S;
Diabetes Care; 2016 May; 39(5):694-700. PubMed ID: 27006512
[TBL] [Abstract][Full Text] [Related]
4. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
Zoungas S; de Galan BE; Ninomiya T; Grobbee D; Hamet P; Heller S; MacMahon S; Marre M; Neal B; Patel A; Woodward M; Chalmers J; ; Cass A; Glasziou P; Harrap S; Lisheng L; Mancia G; Pillai A; Poulter N; Perkovic V; Travert F
Diabetes Care; 2009 Nov; 32(11):2068-74. PubMed ID: 19651921
[TBL] [Abstract][Full Text] [Related]
5. ADVANCE: breaking new ground in type 2 diabetes.
Chalmers J; Perkovic V; Joshi R; Patel A
J Hypertens Suppl; 2006 Aug; 24(5):S22-8. PubMed ID: 16936533
[TBL] [Abstract][Full Text] [Related]
6. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.
Patel A; ; MacMahon S; Chalmers J; Neal B; Woodward M; Billot L; Harrap S; Poulter N; Marre M; Cooper M; Glasziou P; Grobbee DE; Hamet P; Heller S; Liu LS; Mancia G; Mogensen CE; Pan CY; Rodgers A; Williams B
Lancet; 2007 Sep; 370(9590):829-40. PubMed ID: 17765963
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation.
J Hypertens Suppl; 2001 Nov; 19(4):S21-8. PubMed ID: 11848259
[TBL] [Abstract][Full Text] [Related]
8. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial.
Beulens JW; Patel A; Vingerling JR; Cruickshank JK; Hughes AD; Stanton A; Lu J; McG Thom SA; Grobbee DE; Stolk RP; ;
Diabetologia; 2009 Oct; 52(10):2027-36. PubMed ID: 19633827
[TBL] [Abstract][Full Text] [Related]
9. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial.
Chalmers J; Arima H; Woodward M; Mancia G; Poulter N; Hirakawa Y; Zoungas S; Patel A; Williams B; Harrap S
Hypertension; 2014 Feb; 63(2):259-64. PubMed ID: 24324048
[TBL] [Abstract][Full Text] [Related]
10. Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
Tian J; Ohkuma T; Cooper M; Harrap S; Mancia G; Poulter N; Wang JG; Zoungas S; Woodward M; Chalmers J
Diabetes Care; 2020 Jun; 43(6):1293-1299. PubMed ID: 32193249
[TBL] [Abstract][Full Text] [Related]
11. What matters in ADVANCE and ADVANCE-ON.
Hamet P
Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():20-9. PubMed ID: 22118707
[TBL] [Abstract][Full Text] [Related]
12. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
Hirakawa Y; Arima H; Zoungas S; Ninomiya T; Cooper M; Hamet P; Mancia G; Poulter N; Harrap S; Woodward M; Chalmers J
Diabetes Care; 2014 Aug; 37(8):2359-65. PubMed ID: 24812434
[TBL] [Abstract][Full Text] [Related]
13. Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE.
Poulter NR
J Hypertens Suppl; 2009 May; 27(1):S3-8. PubMed ID: 19483505
[TBL] [Abstract][Full Text] [Related]
14. Response of 1,5-anhydroglucitol level to intensive glucose- and blood-pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial.
Selvin E; Wang D; McEvoy JW; Juraschek SP; Lazo M; Hamet P; Cooper ME; Marre M; Williams B; Harrap S; Chalmers J; Woodward M
Diabetes Obes Metab; 2019 Aug; 21(8):2017-2023. PubMed ID: 31050156
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes.
Mohammedi K; Woodward M; Marre M; Colagiuri S; Cooper M; Harrap S; Mancia G; Poulter N; Williams B; Zoungas S; Chalmers J
Cardiovasc Diabetol; 2017 Jul; 16(1):95. PubMed ID: 28750645
[TBL] [Abstract][Full Text] [Related]
16. Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial.
Batty GD; Li Q; Czernichow S; Neal B; Zoungas S; Huxley R; Patel A; de Galan BE; Woodward M; Hamet P; Harrap SB; Poulter N; Chalmers J;
J Am Coll Cardiol; 2010 Nov; 56(23):1908-13. PubMed ID: 21109113
[TBL] [Abstract][Full Text] [Related]
17. Renal protection: What have we learnt from ADVANCE about kidney disease in type 2 diabetes?
Knudsen ST; Cooper ME
Diabetes Obes Metab; 2020 Apr; 22 Suppl 2():12-18. PubMed ID: 31729127
[TBL] [Abstract][Full Text] [Related]
18. [The prevention of the hypertension related damage in type-2 diabetes: the first step of the ADVANCE trial].
Nagy V
Orv Hetil; 2008 Jan; 149(1):19-22. PubMed ID: 18089478
[TBL] [Abstract][Full Text] [Related]
19. Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation.
van der Leeuw J; Visseren FL; Woodward M; Zoungas S; Kengne AP; van der Graaf Y; Glasziou P; Hamet P; MacMahon S; Poulter N; Grobbee DE; Chalmers J
Hypertension; 2015 Jan; 65(1):115-21. PubMed ID: 25312436
[TBL] [Abstract][Full Text] [Related]
20. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
de Galan BE; Zoungas S; Chalmers J; Anderson C; Dufouil C; Pillai A; Cooper M; Grobbee DE; Hackett M; Hamet P; Heller SR; Lisheng L; MacMahon S; Mancia G; Neal B; Pan CY; Patel A; Poulter N; Travert F; Woodward M;
Diabetologia; 2009 Nov; 52(11):2328-2336. PubMed ID: 19688336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
